Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21492
10.3322/caac.21492 · External reference
10.1084/jem.137.5.1142
10.1084/jem.137.5.1142 · External reference
Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice
10.1073/pnas.75.10.5132 · 1978 · External reference
10.1146/annurev.immunol.18.1.767
10.1146/annurev.immunol.18.1.767 · External reference
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
10.1200/jco.2005.04.5252 · 2006 · External reference
10.1080/2162402x.2019.1638212
10.1080/2162402x.2019.1638212 · External reference
10.3389/fcell.2020.00017
10.3389/fcell.2020.00017 · External reference
10.1016/j.coi.2017.01.002
10.1016/j.coi.2017.01.002 · External reference
Dendritic cells in antitumor immune responses
10.1006/cimm.1996.0139 · 1996 · External reference
10.1038/sj.bjc.6601243
10.1038/sj.bjc.6601243 · External reference
Minimal recruitment and activation of dendritic cells within renal cell carcinoma
1998 · External reference
10.1182/blood.v98.10.2992
10.1182/blood.v98.10.2992 · External reference
Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy
10.3389/fimmu.2018.03176 · 2019 · External reference
10.1038/s41577-019-0210-z
10.1038/s41577-019-0210-z · External reference
Acquisition of lymphokine-producing phenotype by CD4+ T cells
10.1146/annurev.iy.12.040194.003223 · 1994 · External reference
10.1002/eji.1830260323
10.1002/eji.1830260323 · External reference
10.1016/s1074-7613(00)80614-7
10.1016/s1074-7613(00)80614-7 · External reference
10.1002/eji.1830260736
10.1002/eji.1830260736 · External reference
Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy
2002 · External reference
10.1074/jbc.m705100200
10.1074/jbc.m705100200 · External reference
Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells
10.1016/j.humimm.2013.01.014 · 2013 · External reference
Transpresentation of interleukin-15 by IL-15/IL-15Ralpha mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
10.18632/oncotarget.6536 · 2015 · External reference
Monocyte-derived dendritic cells with Silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion
10.1158/2326-6066.cir-16-0336 · 2017 · External reference
A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment
10.1182/blood.v96.10.3499 · 2000 · External reference
10.1038/nature23270
10.1038/nature23270 · External reference
Activation of human dendritic cells through CD40 cross-linking
10.1084/jem.180.4.1263 · 1994 · External reference
Costimulation of CD28- T lymphocytes by 4-1BB ligand
10.4049/jimmunol.158.2.551 · 1997 · External reference
10.1002/eji.1830231037
10.1002/eji.1830231037 · External reference
10.1111/j.1600-065x.2009.00770.x
10.1111/j.1600-065x.2009.00770.x · External reference
10.1101/gad.314617.118
10.1101/gad.314617.118 · External reference
10.1634/theoncologist.2011-0122
10.1634/theoncologist.2011-0122 · External reference
10.1111/febs.15028
10.1111/febs.15028 · External reference
Cancer vaccines in ovarian cancer: how can we improve?
10.3390/biomedicines4020010 · 2016 · External reference
Engineering dendritic cell vaccines to improve cancer immunotherapy
10.1038/s41467-019-13368-y · 2019 · External reference
Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines
10.1016/j.copbio.2020.02.009 · 2020 · External reference
10.1158/1078-0432.ccr-13-1185
10.1158/1078-0432.ccr-13-1185 · External reference
10.4049/jimmunol.172.10.5973
10.4049/jimmunol.172.10.5973 · External reference
Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells
10.1038/sj.gt.3302874 · 2007 · External reference
10.1016/j.clim.2008.02.001
10.1016/j.clim.2008.02.001 · External reference
Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors
10.1007/s00262-005-0051-4 · 2006 · External reference
siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells
10.1182/blood-2010-04-278739 · 2010 · External reference
Does the immunocompetent status of cancer patients have an impact on therapeutic DC vaccination strategies?
10.3390/vaccines6040079 · 2018 · External reference
Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors
10.1182/blood.v96.1.91 · 2000 · External reference
Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery
10.1097/00002371-200309000-00008 · 2003 · External reference
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results
10.1186/s40425-015-0055-3 · 2015 · External reference
10.1097/cji.0b013e318183db02
10.1097/cji.0b013e318183db02 · External reference
Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation
2010 · External reference
Potency of mature CD40L RNA electroporated dendritic cells correlates With IL-12 secretion by tracking multifunctional CD8+/CD28+ cytotoxic T-cell responses in vitro
10.1097/cji.0b013e3181fb651a · 2011 · External reference
10.1016/j.smim.2009.05.010
10.1016/j.smim.2009.05.010 · External reference
10.1111/j.1600-065x.2009.00782.x
10.1111/j.1600-065x.2009.00782.x · External reference
10.2147/itt.s163614
10.2147/itt.s163614 · External reference
Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes
10.1038/sj.cgt.7700842 · 2005 · External reference
The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses
10.1189/jlb.0810466 · 2011 · External reference
CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model
2014 · External reference
10.1016/s1074-7613(00)00026-1
10.1016/s1074-7613(00)00026-1 · External reference
10.5041/rmmj.10179
10.5041/rmmj.10179 · External reference
10.2177/jsci.39.18
10.2177/jsci.39.18 · External reference
10.5114/ceji.2018.77390
10.5114/ceji.2018.77390 · External reference
10.1038/nrc1586
10.1038/nrc1586 · External reference
10.1111/j.1600-065x.2006.00442.x
10.1111/j.1600-065x.2006.00442.x · External reference
10.1038/nrc.2015.5
10.1038/nrc.2015.5 · External reference
10.1038/onc.2008.267
10.1038/onc.2008.267 · External reference
Human NK cells and NK receptors
10.1016/j.imlet.2013.12.009 · 2014 · External reference
10.1016/b978-0-7020-6896-6.00017-x
10.1016/b978-0-7020-6896-6.00017-x · External reference
